T. Rowe Price Associates
NGEN

T. Rowe Price Associates’s NervGen Pharma NGEN Stock Holding History

T. Rowe Price Associates’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32K Hold
15,504
– – ﹤0.01% 3211
2026
Q1 		$59K Buy
+15,504
New +$67.2K ﹤0.01% 3061

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

T. Rowe Price Associates's NGEN Position: Q2 2026 in Review

T. Rowe Price Associates held its NervGen Pharma (NGEN) position steady in Q2 2026 at 15,504 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #3211.

T. Rowe Price Associates first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $59K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • T. Rowe Price Associates held 15,504 shares of NervGen Pharma worth $32K as of Q2 2026.
  • T. Rowe Price Associates left its NervGen Pharma share count unchanged in Q2 2026.
  • NervGen Pharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3211 holding.
  • T. Rowe Price Associates first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • T. Rowe Price Associates's NervGen Pharma position peaked at $59K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.